EUVIMEDEUVIMED entdecken
Crossref

FDA Approves Gene Therapy for Younger Children With Sickle Cell Disease

Samantha Anderer

JAMA · 18.08.2026 · 336 (7) · 539

DOI: 10.1001/jama.2026.9488 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, erschienen am 18.08.2026. Verfasst von Samantha Anderer.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The US Food and Drug Administration (FDA) issued supplemental approval of a gene therapy for patients aged 2 years or older with either sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent β-thalassemia.

Zitieren

APA

Anderer, S. (2026). FDA Approves Gene Therapy for Younger Children With Sickle Cell Disease. JAMA, 336(7), 539. https://doi.org/10.1001/jama.2026.9488

Vancouver

Anderer S. FDA Approves Gene Therapy for Younger Children With Sickle Cell Disease. JAMA. 2026;336(7):539. doi:10.1001/jama.2026.9488

BibTeX
@article{Anderer2026,
  author = {Anderer, Samantha},
  title = {FDA Approves Gene Therapy for Younger Children With Sickle Cell Disease},
  journal = {JAMA},
  year = {2026},
  volume = {336},
  number = {7},
  pages = {539},
  doi = {10.1001/jama.2026.9488}
}
Kostenlos starten →